HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

Journal of Cellular Physiology

Volumn 205, Issue 1, 2005, Pages 10-18

  Pupa, Serenella M ^a   Tagliabue, Elda ^a   Ménard, Sylvie ^a   Anichini, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; CD45RO ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; DNA VACCINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; ONCOPROTEIN; PACLITAXEL; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UVOMORULIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; B LYMPHOCYTE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; ONCOGENE NEU; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; BREAST NEOPLASMS; HUMANS; IMMUNOTHERAPY; RECEPTOR, ERBB-2; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 24344474832     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20387     Document Type: Review

References (81)

1. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX. 2002. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137.
2. Anderson BW, Peoples GE, Murray JL, Gillogly MA, Gershenson DM, Ioannides CG. 2000. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin Cancer Res 6:4192-4200.
3. Baxevanis CN, Sotiropoulou PA, Sotiriadou NN, Papamichail M. 2004. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 53:166-175.
4. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. 2002. Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 9:33-44.
5. Brinkman JA, Fausch SC, Weber JS, Kast WM. 2004. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 4:181-198.
6. Burstein HJ. 2004. Trastuzumab in combination with chemotherapy. Breast Cancer Res Treat 2003:869-872.
7. Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP. 2003. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study. J Clin Oncol 21:46-53.
8. Castilleja A, Ward NE, O'Brian CA, Swearingen B, Swan E, Gillogly MA, Murray JL, Kudelka AP, Gershenson DM, Ioannides CG. 2001. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol Cell Biochem 217:21-33.
9. Castilleja A, Carter D, Efferson CL, Ward NE, Kawano K, Fisk B, Kudelka AP, Gershenson DM, Murray JL, O'Brian CA, Ioannides CG. 2002. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. J Immunol 169:3545-3554.
10. Cefai D, Morrison BW, Sckell A, Favre L, Balli M, Leunig M, Gimmi CD. 1999. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int J Cancer 83:393-400.
11. Clynes RA, Towers TL, Presta LG, Ravetch JV. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443-446.
12. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.
13. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J. 1999. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59:1196-1201.
14. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, Spadaro M, Colombo MP, Amici A, Lollini PL, Musiani P, Forni G. 2003. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 111:1161-1170.
15. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949.
16. Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, Reilly RT, Kaumaya PT. 2005. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem 280:54-63.
17. Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML. 2003. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 21:1317-1326.
18. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA. 1994. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-20.
19. Disis ML, Pupa SM, Gralow JR, Dittadi R, Ménard S, Cheever MA. 1997. High titer HER-2/neu protein specific antibody immunity can be detected in patients with early stage breast cancer. J Clin Oncol 15:3363-3367.
20. Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela RC, Schiffman K. 2002. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers. Blood 99:2845-2850.
21. Early Breast Cancer Trialists' Collaborative Group. 1998. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467.
22. Efferson CL, Schickli J, Ko BK, Kawano K, Mouzi S, Palese P, Garcia-Sastre A, Ioannides CG. 2003. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene. J Virol 77:7411-7424.
23. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V, Umansky V. 2001. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7:452-458.
24. Finn OJ. 2003. Cancer vaccines: Between the idea and the reality. Nat Rev Immunol 3:630-641.
25. Gennari R, Ménard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A. 2004. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650-5655.
26. Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL. 2004. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 53:490-496.
27. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. 2002. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: Implications for antibody-based therapeutics of cancer. Cancer Res 62:6891-6900.
28. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK. 2002. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100:3155-3163.
29. Herrmann F, Lehr HA, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B. 2004. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64:215-220.
30. Hurwitz E, Stancovski I, Sela M, Yarden Y. 1995. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA 92:3353-3357.
31. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA. 1993. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 151:225-234.
32. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. 2002. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416:279-280.
33. Klapper LN, Waterman H, Sela M, Yarden Y. 2000. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60:3384-3388.
34. Knutson KL, Schiffman K, Disis ML. 2001. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477-484.
35. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Hong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ. 2003. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142-153.
36. Kono K, Sato E, Naganuma H, Takahashi A, Mimura K, Nukui H, Fujii H. 2004. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes. Clin Cancer Res 10: 2538-2544.
37. Kreitman RJ. 2003. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 5:44-51.
38. Kuerer HM, Peoples GE, Sahin AA, Murray JL, Singletary SE, Castilleja A, Hunt KK, Gershenson DM, Ioannides CG. 2002. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res 22:583-592.
39. Lee K-F, Simon H, Chen H, Bates B, Hung M-C, Hauser C. 1995. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378: 394-398.
40. Liu Y, El-Ashry D, Chen D, Ding IYF, Kern FG. 1995. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117.
41. Lollini PL, Forni G. 2002. Antitumor vaccines: Is it possible to prevent a tumor? Cancer Immunol Immunother 51:409-416.
42. Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, Subjeck JR. 2003. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 171:4054-4061.
43. Meyer D, Birchmeier C. 1995. Multiple essential functions of neuregulin in development. Nature 378:386-390.
44. Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. 2004. Role of HER2/ neu in tumor progression and therapy. Cell Mol Life Sci 61:2965-2978.
45. Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C. 2000. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 60:4850-4854.
46. Nahta R, Hung MC, Esteva FJ. 2004. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64:2343-2346.
47. Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini P-L. 2001. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 194:1-12.
48. Ohashi PS, DeFranco AL. 2002. Making and breaking tolerance. Curr Opin Immunol 14:744-759.
49. Ostrand-Rosenberg S. 2004. Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 16:143-150.
50. Pandolfi PP. 2004. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 351:2337-2338.
51. Parihar R, Dierksheide J, Hu Y, Carson WE. 2002. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 110:983-992.
52. Pegram M, Slamon D. 2000. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 27:13-19.
53. Perez SA, Sotiropoulou PA, Sotiriadou NN, Mamalaki A, Gritzapis AD, Echner H, Voelter W, Pawelec G, Papamichail M, Baxevanis CN. 2002. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. Cancer Immunol Immunother 50:615-624.
54. Piechocki MP, Pilon SA, Wei WZ. 2001. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 167:3367-3374.
55. Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, Di Fiore PP, Aaronson SA. 1991. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 6:1189-1194.
56. Press MF, Cordon-Cardo C, Slamon DJ. 1990. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5:953-962.
57. Pupa SM, Ménard S, Andreola S, Colnaghi MI. 1993. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53:5864-5866.
58. Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnaghi MI, Ménard S. 1996. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. J Clin Oncol 14:85-94.
59. Pupa SM, Invernizzi AM, Forti S, Nanni P, Lollini PL, Meazza R, Ferrini S, Ménard S. 2001. Prevention of neu-expressing breast tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 8:75-79.
60. Pupa SM, Iezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R, Comes A, Ferrini S, Musiani P, Ménard S. 2005. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 65:1071-1078.
61. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F. 2004. Electroporated DNA vaccine clears away multifocal mammary carcinomas in HER-2/neu transgenic mice. Cancer Res 64:2858-2864.
62. Rentzsch C, Kayser S, Stumm S, Watermann I, Walter S, Stevanovic S, Wallwiener D, Guckel B. 2003. Evaluation of pre-existent immunity in patients with primary breast cancer: Molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 9:4376-4386.
63. Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS. 2003. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: A pilot study. Clin Cancer Res 9:2440-2446.
64. Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC. 2004. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 64:8022-8028.
65. Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML. 2003. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 9:5559-5565.
66. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K. 2002. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900-5906.
67. Sibilia M, Steinbach JP, Stingl L, Aguzzi A, Wagner EF. 1998. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J 17:719-731.
68. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792.
69. Sotiropoulou PA, Perez SA, Iliopoulou EG, Missitzis I, Voelter V, Echner H, Baxevanis CN, Papamichail M. 2003. Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours. Br J Cancer 89:1055-1061.
70. Spadaro M, Lanzardo S, Curcio C, Forni G, Cavallo F. 2004. Immunological inhibition of carcinogenesis. Cancer Immunol Immunother 53:204-216.
71. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES. 2002. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8:1720-1730.
72. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR. 2004. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526.
73. Tanaka Y, Amos KD, Joo HG, Eberlein TJ, Goedegebuure PS. 2001. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes. Int J Cancer 94:540-544.
74. Tanaka Y, Dowdy SF, Linehan DC, Eberlein TJ, Goedegebuure PS. 2003. Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells. J Immunol 170:1291-1298.
75. Toth J, Kubes M. 1993. Masking of HLA class I molecules expressed on K-562 target cells can restore their susceptibility to NK cell cytolysis. Immunobiology 188:134-144.
76. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. 2002. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87:21-27.
77. Xu S, Koski GK, Faries M, Bedrosian I, Mick R, Maeurer M, Cheever MA, Cohen PA, Czerniecki BJ. 2003. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 171:2251-2261.
78. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. 2002. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132-4141.
79. Zaks TZ, Rosenberg SA. 1998. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58:4902-4908.
80. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lofae MT, Storkus WJ. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87-97.
81. zum Buschenfelde CM, Metzger J, Hermann C, Nicklisch N, Peschel C, Bernhard H. 2001. The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J Immunol 167:1712-1719.